{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:10:59Z","timestamp":1790244659769,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011594","name":"Penn State College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Claudin 18 (CLDN18) is a protein that functions to maintain the integrity of tight junctions in epithelial cells. Recent development of anti-Claudin 18.2 targeted therapies have yielded positive survival outcomes for patients with Claudin 18 expression in gastric carcinomas. This study aims to investigate whether expression of Claudin 18 is present in a variety of benign and malignant salivary gland neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty-eight cases of salivary gland neoplasms of various subtypes were included for this pilot study. Ancillary data including tumor location, grade, and stage of tumor as applicable was collected. Claudin 18 immunohistochemistry was performed on a representative tumor block of each case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No aberrant Claudin 18 expression was seen in the benign as well as malignant salivary gland neoplasms in this pilot study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CLDN18 expression was uniformly absent across the tumor types, locations, grades, and stages represented in this cohort. The absence of expression in all cases indicates that Claudin 18 has limited potential as a therapeutic marker in patients with salivary gland neoplasms. This study contributes to the extremely limited literature regarding Claudin 18 expression within salivary gland neoplasms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12105-026-01972-6","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:38:03Z","timestamp":1790242683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Claudin 18 Immunohistochemistry Expression in Salivary Gland Neoplasms: Limited Potential as a Therapeutic Biomarker"],"prefix":"10.1007","volume":"20","author":[{"given":"Nicole","family":"Fye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanica","family":"Bhele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"1972_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02905-z","volume":"42","author":"K Imran","year":"2025","unstructured":"Imran K, Iqbal MJ, Ahmed MM et al (2025) Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies. Med Oncol 42:359. https:\/\/doi.org\/10.1007\/s12032-025-02905-z","journal-title":"Med Oncol"},{"key":"1972_CR2","unstructured":"UniProt Consortium. Claudin-18 (P56856) UniProt. Available from: https:\/\/www.uniprot.org\/uniprotkb\/P56856\/entry"},{"key":"1972_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y et al (2024) Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 21:354\u2013369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1972_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113491","volume":"28","author":"Y Liu","year":"2025","unstructured":"Liu Y, Huang W, Hsu JC, Sun Z, Cai W, Kang L (2025) Targeting Claudin18.2 for cancer theranostics: from molecular imaging to precision therapy. iScience 28(10):113491. https:\/\/doi.org\/10.1016\/j.isci.2025.113491","journal-title":"iScience"},{"key":"1972_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/jcp-2025-210328","volume":"79","author":"G Murtazaalieva","year":"2026","unstructured":"Murtazaalieva G, Baldwin A, Fassan M et al (2026) Claudin 18.2 in cancer research and treatment: a pathologist\u2019s perspective. J Clin Pathol 79:148\u2013160","journal-title":"J Clin Pathol"},{"key":"1972_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120258","author":"M Ghasemian","year":"2025","unstructured":"Ghasemian M, Mohammad AG, Mohammad JF et al (2025) Heterogeneity in benign and malignant salivary gland tumors. Clin Chim Acta. https:\/\/doi.org\/10.1016\/j.cca.2025.120258","journal-title":"Clin Chim Acta"},{"key":"1972_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/curroncol32040232","volume":"32","author":"S Sreenivasan","year":"2025","unstructured":"Sreenivasan S, Jiwani R, White R et al (2025) Advances in targeted and systemic therapy for salivary gland carcinomas: current options and future directions. Curr Oncol 32:232. https:\/\/doi.org\/10.3390\/curroncol32040232","journal-title":"Curr Oncol"},{"key":"1972_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153161","author":"CF Joca de Arruda","year":"2020","unstructured":"Joca de Arruda CF, Coutinho-Camillo CM, Marques MM et al (2020) Claudin expression is maintained in mucoepidermoid carcinoma of the salivary gland. Pathol Res Pract. https:\/\/doi.org\/10.1016\/j.prp.2020.153161","journal-title":"Pathol Res Pract"},{"issue":"4","key":"1972_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71799","volume":"15","author":"LA Brust","year":"2026","unstructured":"Brust LA, K\u00fchn JP, K\u00f6rner S, Knebel M, Braun FL, Zeidan P, Wemmert S, Schick B, Smola S, Wagner M, Ertz M, Linxweiler M (2026) Immunohistochemical analysis of potential therapeutic targets PRAME, FOLR1, and CLDN18.2 in salivary gland carcinomas. Cancer Med 15(4):e71799. https:\/\/doi.org\/10.1002\/cam4.71799","journal-title":"Cancer Med"},{"issue":"5","key":"1972_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ueno Y, Wang X, Shah MA (2024) Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27(5):1058\u20131068. https:\/\/doi.org\/10.1007\/s10120-024-01518-1","journal-title":"Gastric Cancer"},{"key":"1972_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.21.00449","volume":"39","author":"JL Geiger","year":"2021","unstructured":"Geiger JL, Ismaila N, Beadle B et al (2021) Management of salivary gland malignancy: ASCO guideline. J Clin Oncol 39:1909\u20131941. https:\/\/doi.org\/10.1200\/JCO.21.00449","journal-title":"J Clin Oncol"},{"key":"1972_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00418-007-0322-6","volume":"128","author":"SV Louren\u00e7o","year":"2007","unstructured":"Louren\u00e7o SV, Coutinho-Camillo CM, Buim ME et al (2007) Human salivary gland branching morphogenesis: morphological localization of claudins and its parallel relation with developmental stages revealed by expression of cytoskeleton and secretion markers. Histochem Cell Biol 128:361\u2013369. https:\/\/doi.org\/10.1007\/s00418-007-0322-6","journal-title":"Histochem Cell Biol"},{"issue":"5","key":"1972_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5858\/arpa.2021-0428-oa","volume":"147","author":"MT Wong","year":"2022","unstructured":"Wong MT, Singhi AD, Larson BK et al (2022) Claudin-18: patterns of expression in the upper gastrointestinal tract and utility as a marker of gastric origin in neuroendocrine tumors. Arch Pathol Lab Med 147(5):559\u2013567. https:\/\/doi.org\/10.5858\/arpa.2021-0428-oa","journal-title":"Arch Pathol Lab Med"},{"key":"1972_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611328","volume":"29","author":"M Gyulai","year":"2023","unstructured":"Gyulai M, Harko T, Fabian K, Karsko L, Agocs L, Szigeti B, Fillinger J, Szallasi Z, Pipek O, Moldvay J (2023) Claudin expression in pulmonary adenoid cystic carcinoma and mucoepidermoid carcinoma. Pathol Oncol Res 29:1611328. https:\/\/doi.org\/10.3389\/pore.2023.1611328","journal-title":"Pathol Oncol Res"},{"key":"1972_CR15","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s40262-025-01552-x","volume":"64","author":"J Yang","year":"2025","unstructured":"Yang J, Yamada A, Shitara K et al (2025) Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab. Clin Pharmacokinet 64:1465\u20131476. https:\/\/doi.org\/10.1007\/s40262-025-01552-x","journal-title":"Clin Pharmacokinet"},{"key":"1972_CR16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668","journal-title":"Lancet"},{"issue":"6","key":"1972_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrgastro.2013.35","volume":"10","author":"ME Johansson","year":"2013","unstructured":"Johansson ME, Sj\u00f6vall H, Hansson GC (2013) The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 10(6):352\u2013361. https:\/\/doi.org\/10.1038\/nrgastro.2013.35","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1972_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-026-01793-9","author":"T Bian","year":"2026","unstructured":"Bian T, Ren X, Jiang D et al (2026) CLDN18.2 expression identifies a gastric-type phenotype and a potential therapeutic target in pulmonary invasive mucinous adenocarcinoma. Diagn Pathol. https:\/\/doi.org\/10.1186\/s13000-026-01793-9","journal-title":"Diagn Pathol"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-026-01972-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:38:05Z","timestamp":1790242685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-026-01972-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1007\/s12105-026-01972-6","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"15 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, formal consent is not required. Institutional review board (IRB) approval was granted for this research.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study informed consent is not required.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study consent for publication is not required.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}